Urodynamix Technologies Ltd. Announces $1.5 Million Private Placement

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it is
raising a minimum of $1,500,000 through the issuance of 30,000,000 common shares
of the Company at a price of $0.05 per common share. BC Advantage Funds has
provided the Company with a lead order of $750,000.


The Company may over allot the private placement to raise a maximum of
$2,000,000. The Company will pay a commission of up to 7.5% on sales of common
shares to third parties. There is no commission payable on the investment by
current shareholders, including BC Advantage Funds.


The securities issued by this non-brokered private placement will be subject to
a four month hold from the date of closing and the placement is subject to
regulatory approval. Proceeds from this private placement will be used to
accelerate the sales of the Company's uroNIRS 2000, a non-invasive diagnostic
approved for the diagnosis of urological conditions, and for general working
capital purposes.


"We are pleased to announce this private placement with the support and
participation from our major shareholders and management team. This financing
will provide the Company with sufficient resources to execute on our business
plan, specifically to accelerate the sales of our uroNIRS 2000 in the USA and to
drive the Company to profitability." said Barry Allen, President and Chief
Executive Officer. "The Company has taken steps to significantly reduce its cash
burn and has narrowed its focus to products that it believes will have
significant near term financial impact."


About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic
hyperplasia, and traumatic increases in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.

Urodynamix Technologies Ltd. (TSXV:URO)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024